\captionsetup[table]{labelformat=empty,skip=1pt}
\begin{longtable}{lcrr}
\caption*{
\large \textbf{Resultados de validación externa de modelos de referencia}\\ 
\small \\ 
} \\ 
\toprule
\textbf{Estudio}\textsuperscript{1} & \textbf{N} & \textbf{MPE {[}IC95\%{]}} & \textbf{RMSE} \\ 
\midrule
Rhodes et al (TAD) & 90 & $1.420$ [$-0.873$, $3.713$] & $1.836$ \\ 
Rhodes et al (TSFD) & 90 & $1.412$ [$-0.853$, $3.678$] & $1.821$ \\ 
Whited et al (TAD) & 90 & $0.836$ [$-0.656$, $2.328$] & $1.128$ \\ 
Whited et al (TSFD) & 90 & $0.834$ [$-0.653$, $2.321$] & $1.124$ \\ 
\bottomrule
\end{longtable}
\vspace{-5mm}
\begin{minipage}{\linewidth}
\textsuperscript{1}{[}1{]} Whited L, Grove M, Rose D, et al. Pharmacokinetics of Cefepime in Patients with Cancer and Febrile Neutropenia in the Setting of Hematologic Malignancies or Hematopoeitic Cell Transplantation. Pharmacother J Hum Pharmacol Drug Ther 2016; 36: 1003--1010.
{[}2{]} Rhodes NJ, Grove ME, Kiel PJ, et al. Population pharmacokinetics of cefepime in febrile neutropenia: implications for dose-dependent susceptibility and contemporary dosing regimens. Int J Antimicrob Agents 2017; 50: 482--486. \\ 
\end{minipage}

